Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1974 1
1975 1
1976 1
1984 1
1992 1
1993 1
1995 1
1996 2
1997 5
1998 5
1999 5
2000 4
2001 1
2002 1
2003 1
2005 2
2006 1
2008 5
2009 6
2010 4
2011 3
2012 4
2013 5
2014 5
2015 5
2016 5
2017 3
2018 2
2019 2
2020 3
2021 7
2022 9
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Results by year

Filters applied: . Clear all
Page 1
Golf-related ocular injuries.
Pollack JS, Mieler WF, Mittra RA. Pollack JS, et al. Among authors: mittra ra. Curr Opin Ophthalmol. 1997 Jun;8(3):15-8. doi: 10.1097/00055735-199706000-00004. Curr Opin Ophthalmol. 1997. PMID: 10168889 Review.
Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma.
Seneviratne JA, Carter DR, Mittra R, Gifford A, Kim PY, Luo JS, Mayoh C, Salib A, Rahmanto AS, Murray J, Cheng NC, Nagy Z, Wang Q, Kleynhans A, Tan O, Sutton SK, Xue C, Chung SA, Zhang Y, Sun C, Zhang L, Haber M, Norris MD, Fletcher JI, Liu T, Dilda PJ, Hogg PJ, Cheung BB, Marshall GM. Seneviratne JA, et al. Among authors: mittra r. Int J Cancer. 2023 Apr 1;152(7):1399-1413. doi: 10.1002/ijc.34349. Epub 2022 Nov 17. Int J Cancer. 2023. PMID: 36346110 Free PMC article.
Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results.
Regillo C, Berger B, Brooks L, Clark WL, Mittra R, Wykoff CC, Callaway NF, DeGraaf S, Ding HT, Fung AE, Gune S, Le Pogam S, Smith R, Willis JR, Barteselli G. Regillo C, et al. Among authors: mittra r. Ophthalmology. 2023 Jul;130(7):735-747. doi: 10.1016/j.ophtha.2023.02.024. Epub 2023 Mar 2. Ophthalmology. 2023. PMID: 36870451 Free article. Clinical Trial.
Infusion Misdirection in Microincisional Vitrectomy Surgery.
Ryan EH, Halperin LS, Mittra RA, Wong K, Pulido CM. Ryan EH, et al. Among authors: mittra ra. Ophthalmol Retina. 2018 Feb;2(2):112-117. doi: 10.1016/j.oret.2017.06.001. Epub 2017 Sep 1. Ophthalmol Retina. 2018. PMID: 31047337
Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial.
Aref AA, Scott IU, VanVeldhuisen PC, King J, Ip MS, Blodi BA, Oden NL; Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Investigator Group. Aref AA, et al. JAMA Ophthalmol. 2021 Dec 1;139(12):1285-1291. doi: 10.1001/jamaophthalmol.2021.4395. JAMA Ophthalmol. 2021. PMID: 34709363 Free PMC article. Clinical Trial.
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.
Scott IU, Oden NL, VanVeldhuisen PC, Ip MS, Blodi BA; SCORE2 Study Investigator Group. Scott IU, et al. JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352. JAMA Ophthalmol. 2022. PMID: 35323843 Free PMC article. Clinical Trial.
107 results